Pfizer announce positive results from Phase 3 EV-304 trial of PADCEV and Keytruda in bladder cancer
Pfizer (NYSE:PFE) and Astellas have announced positive topline results from the interim analysis of the Phase 3 EV-304 (KEYNOTE-B15) trial, evaluating the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
The trial, which compared the combination therapy to standard cisplatin-based neoadjuvant chemotherapy, met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival (EFS).
Additionally, the trial showed a statistically significant improvement in overall survival (OS), a key secondary endpoint, as well as in pathologic complete response (pCR), further supporting the combination's potential in MIBC treatment.
Safety findings were consistent with the known safety profiles of both drugs.
The results are expected to be presented at an upcoming medical meeting, with discussions planned with global health authorities regarding potential regulatory filings for the combination treatment.
More from United States
Lamar raises 2026 AFFO outlook to $8.97
Lemonade posts $336 million Q3 revenue, narrows loss
BD reveals $5.27 billion Q4 revenue, raises 2027 outlook
Cummins earnings surge to $1.14 billion as sales climb 13%
Six Flags reveals $1.17 billion Q3 revenue amid $366 million loss
EPAM Systems reports $1.43B Q3 revenue, expands buyback to $1.8B
